NCT06073938View on ClinicalTrials.gov

Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Advanced Solid Tumors or Lymphomas
Interventions
DRUG

NHWD-870

The base dosage administered is 2.0 mg/dose/day, and the frequency and dose of administration may be adjusted based on safety data.

Trial Locations (1)

410013

RECRUITING

Hunan Provincal Tumor Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER